[Asia Economy Reporter Lee Seon-ae]
▲SK Bioscience=Applied for IND of Phase 3 clinical trial in Nepal for heterologous booster shot of COVID-19 vaccine GBP510
▲CJ CheilJedang=Preliminarily estimated consolidated operating profit for Q2 this year at KRW 504.3 billion, up 7.4% from the same period last year
▲CJ Logistics=Preliminarily estimated consolidated operating profit for Q2 this year at KRW 116.1 billion, up 28.2% from the same period last year
▲Youngheung=Decided on a KRW 7 billion debt guarantee for subsidiary Daehotuksugang
▲Kia=Purchased other securities worth KRW 20 billion from Hyundai Motor Securities for stable fund management and profitability improvement
▲LX Hausys=Decided to increase short-term borrowings by KRW 50 billion for operating fund procurement
▲Inbiogen=Decided on a KRW 30 billion third-party allotment capital increase
▲Korea Asset Trust=Decided to purchase commercial paper (CP) worth KRW 60 billion from affiliate Korea Asset Capital
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
